Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad's Q4 Revenues Jump 34 Percent, But Charges Hit Profit

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories today reported a 34 percent increase in fourth-quarter revenues, helped by the acquisition of diagnostics firm DiaMed, while its profit dipped 25.3 percent due to charges related to that acquisition.
 
The Hercules, Calif.-based firm had fourth-quarter 2007 revenues of $459.7 million compared to revenues of $343.1 million in the comparable period the year before. Though revenue growth was 34 percent, excluding the contribution from DiaMed, revenues increased 15.9 percent year over year, said Bio-Rad.
 
Its life science segment sales were $184.5 million, up 16.1 percent year over year, and clinical diagnostics segment sales were up 50.7 percent at $271.4 million. Excluding DiaMed’s contribution, sales for the segment were up 16.3 percent.
 
The firm’s net income dropped to $12.4 million, or $.45 per share, from $16.6 million, or $.61 per share. Bio-Rad recognized non-cash charges of $12.9 million in the quarter related to purchased in-process R&D and amortization of intangibles tied to the DiaMed acquisition.
 
Bio-Rad’s R&D costs climbed 19.8 percent to $39.9 million from $33.3 million year over year, while SG&A expenses increased 33.1 percent to $163 million from $122.5 million.
 
For full-year 2007, Bio-Rad reported revenues of $1.46 billion, up 14.7 percent from revenues of $1.27 billion in 2006. Sales for the life sciences segment grew 6.9 percent to $615.1 million, while clinical diagnostics sales increased 21.5 percent to $832.2 million.
 
The firm’s net income slipped 10 percent to $93 million, or $3.41 per share, from $103.3 million, or $3.83 per share. Last year’s results include $11.7 million in revenue from a legal settlement with bioMérieux.
 
Bio-Rad’s R&D expenses in 2007 increased 13.9 percent to $140.6 million from $123.4 million, while SG&A expenses were up 15.7 percent at $508 million versus $438.9 million the year before.
 
The firm finished the year with $161.8 million in cash and cash equivalents.
The Scan

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.

US Survey Data Suggests Ancestry Testing Leads Way in Awareness, Use of Genetic Testing Awareness

Although roughly three-quarters of surveyed individuals in a Genetics in Medicine study reported awareness of genetic testing, use of such tests was lower and varied with income, ancestry, and disease history.

Coral Genome Leads to Alternative Amino Acid Pathway Found in Other Non-Model Animals

An alternative cysteine biosynthesis pathway unearthed in the Acropora loripes genome subsequently turned up in sequences from non-mammalian, -nematode, or -arthropod animals, researchers report in Science Advances.

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.